MedCity News June 23, 2024
Frank Vinluan

Ascidian Therapeutics’ technology edits RNA to treat inherited disorders. While the startup’s lead internal program is for the retinal disorder Stargardt disease, its new R&D alliance with Roche will focus on developing RNA-editing therapies for neurological indications.

Biotechnology research has brought patients therapies made by editing DNA. Roche aims be part of the next wave of genetic medicines with a focus on RNA. Its latest move in this strategy is a partnership with Ascidian Therapeutics, a startup with technology that edits RNA to address multiple mutations driving a disease.

According to terms of the alliance announced this past week, Roche is paying $42 million up front for rights to use Ascidian’s RNA exon-editing technology for certain neurological targets. Specific targets...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

 
Topics: Biotechnology, Partnerships, Pharma / Biotech, Trends
At Current Prices GLP-1s Aren’t Cost-Effective, Limiting Access To Patients
Latigo raises $150M to get non-opioid pain drugs through key tests
AstraZeneca Aims to Make Cell Therapy More Accessible With $425M EsoBiotec Acquisition
CMS doubles down on Medicare drug price negotiations
Drug shortages could surge 25% as AI reshapes specialty pharmacy: Survey

Share This Article